Drug Trial Radar · NCT05298800
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
Last checked: Nov 19, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,000
Planned (sponsor's estimate)
Start
Oct 8, 2021
Primary completion
Dec 31, 2022
Study completion Dec 31, 2023
Sponsor
- Lead sponsor
- Centers for Disease Control and Prevention, ChinaGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Mar 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objective of this study was to evaluate the immunogenicity and safety of the booster dose of COVID-19 inactivated vaccine and co-immunization with quadrivalent influenza vaccine and 23-valent pneumonia polysaccharide vaccine in people aged 18 years and older. A randomized controlled, open trial design was adopted. The study was conducted with informed consent of the subjects for immunogenicity and safety in the population aged 18 years and older. A total of 3000 healthy subjects were selected, (1)600 healthy subjects were selected for the immunogenicity and safety study of co-immunization, 300 in the adult group (18-59 years old) and 300 in the elderly group (60 years old and above); (2) 2400 healthy subjects were selected for the observational study of the safety of co-immunization, 1200 in the adult group (18-59 years old) and 1200 in the elderly group (60 years old and above ) 1200 people.
Conditions
- Safety
- Immunogenicity, Vaccine
- COVID-19 Vaccines
- Influenza Vaccines
- Pneumococcal Vaccines
Interventions
VaccineBiological
Different arms were administrated different vaccines
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seroconversion rate of neutralizing antibodyTime frame: 28 days after the third dose of COVID-19 vaccine
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Daxing District Center of Disease Control and Prevention
Beijing, China · Recruiting
Huairou District Center of Disease Control and Prevention
Beijing, China · Recruiting
Miyun District Center of Disease Control and Prevention
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.